Literature DB >> 9352585

Understanding and manipulating O6-methylguanine-DNA methyltransferase expression.

R O Pieper1.   

Abstract

O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that transfers methyl and alkyl lesions from the O6 position of guanine to a cysteine in its structure. The ability of MGMT to also remove precytotoxic O6-alkylguanine lesions induced by chemotherapeutic chloroethylnitrosoureas has made down-regulation of MGMT expression the key component in strategies designed to sensitize tumors to the cytotoxic potential of chloroethylnitrosoureas. The study of how to regulate MGMT expression at the gene, mRNA, and protein levels has contributed not only to the development of effective inhibitors of MGMT action, but also, in a broader sense, to a better understanding of gene regulation and protein structure/function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352585     DOI: 10.1016/s0163-7258(97)00003-x

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  14 in total

1.  MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.

Authors:  Fateme Salehi; Bernd W Scheithauer; Johann M Kros; Queenie Lau; Michael Fealey; Dana Erickson; Kalman Kovacs; Eva Horvath; Ricardo V Lloyd
Journal:  J Neurooncol       Date:  2011-02-11       Impact factor: 4.130

2.  Bortezomib downregulates MGMT expression in T98G glioblastoma cells.

Authors:  Panagiotis J Vlachostergios; Eleana Hatzidaki; Nikolaos E Stathakis; George K Koukoulis; Christos N Papandreou
Journal:  Cell Mol Neurobiol       Date:  2013-01-20       Impact factor: 5.046

3.  Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA.

Authors:  Nina Mojas; Massimo Lopes; Josef Jiricny
Journal:  Genes Dev       Date:  2007-12-15       Impact factor: 11.361

4.  Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.

Authors:  Jonathon F Parkinson; Helen R Wheeler; Adele Clarkson; Catriona A McKenzie; Michael T Biggs; Nicholas S Little; Raymond J Cook; Marinella Messina; Bruce G Robinson; Kerrie L McDonald
Journal:  J Neurooncol       Date:  2007-11-15       Impact factor: 4.130

5.  Alkylation damage repair protein O6-alkylguanine-DNA alkyltransferase from the hyperthermophiles Aquifex aeolicus and Archaeoglobus fulgidus.

Authors:  Sreenivas Kanugula; Anthony E Pegg
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

6.  Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.

Authors:  Sibille Everhard; Jörg Tost; Hafida El Abdalaoui; Emmanuelle Crinière; Florence Busato; Yannick Marie; Ivo G Gut; Marc Sanson; Karima Mokhtari; Florence Laigle-Donadey; Khê Hoang-Xuan; Jean-Yves Delattre; Joëlle Thillet
Journal:  Neuro Oncol       Date:  2009-02-17       Impact factor: 12.300

7.  Antitumor activity of semisynthetic derivatives of Aconitum alkaloids.

Authors:  Ainura Chodoeva; Jean-Jacques Bosc; Lydia Lartigue; Jean Guillon; Céline Auzanneau; Pierre Costet; Ashiraly Zurdinov; Christian Jarry; Jacques Robert
Journal:  Invest New Drugs       Date:  2013-06-13       Impact factor: 3.850

8.  Splice site and Germline variations of the MGMT gene in Esophageal cancer from Kashmir Valley: India.

Authors:  Mohd Amin Shah; Sheikh M Shaffi; Ghulam Nabi Lone; Syed Mudassar Jan
Journal:  Int J Health Sci (Qassim)       Date:  2013-11

9.  MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Authors:  Alireza Mansouri; Laureen D Hachem; Sheila Mansouri; Farshad Nassiri; Normand J Laperriere; Daniel Xia; Neal I Lindeman; Patrick Y Wen; Arnab Chakravarti; Minesh P Mehta; Monika E Hegi; Roger Stupp; Kenneth D Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

10.  The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.

Authors:  Takuro Hayashi; Kazuhide Adachi; Shigeo Ohba; Yuichi Hirose
Journal:  J Neurooncol       Date:  2013-08-13       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.